LOCF=last observation carried forward.
PRESERVE was a 2-period study of patients (N=834) with moderately active RA (DAS 28 >3.2 and ≤5.1) despite optimal doses of MTX.
Baseline characteristics1 (N=834)
The ITT population (N=411) was defined as all subjects who received at least 1 dose of study drug during Period 2
In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.
In moderate to severe RA
*6-month average of IMS monthly NPA prescription data by rheumatologists.
IMS NPA prescription data does not include products administered by infusion.
To return to ENBREL.com, click "Cancel" or close this window.
Your e-mail was sent successfully.
Send another e-mail
Return to enbrel.com/RheumPro
The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.
If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.